Re-Thinking IP Licenses in the Wake of The Supreme Court's 1/9/07 Decision in Medimmune v. Genentech
22 January 2007
Patent licensing is a critical component of nanotechnology commercialization, where a large volume of licensing facilitates the transfer of technology from universities and government labs into nanotechnology start-up companies. In Medimmune v. Genentech, the Supreme Court opened the door to the possibility that a licensee may attack validity of a licensed patent while continuing to pay royalties under the license agreement and preserving the protection offered by the license agreement, thereby potentially avoiding the risk of an injunction if the attack on validity is unsuccessful.
In Medimmune v. Genentech, the Supreme Court opened the door to the possibility that a licensee may attack validity of a licensed patent while continuing to pay royalties under the license agreement and preserving the protection offered by the license agreement, thereby potentially avoiding the risk of an injunction if the attack on validity is unsuccessful.
Read the complete article by clicking on the link below.
In Medimmune v. Genentech, the Supreme Court opened the door to the possibility that a licensee may attack validity of a licensed patent while continuing to pay royalties under the license agreement and preserving the protection offered by the license agreement, thereby potentially avoiding the risk of an injunction if the attack on validity is unsuccessful.
Read the complete article by clicking on the link below.
Author(s)
Related Insights
17 February 2025
Renewed Prohibition on Use of Sub-Regulatory Guidance – Key to False Claims Act Cases
“It’s déjà vu all over again.” Attorney General Pam Bondi has not surprisingly renewed the prior Trump administration’s prohibition on the use of sub-regulatory guidance, potentially altering the landscape for False Claims Act cases pursued during the second Trump administration.
14 February 2025
Foley Viewpoints
Wastin’ Away in Non-Complianceville
Everyone knows — or should know — that “The Terminator” is the best Halloween movie release and that “Die Hard” is the best Christmas movie (even though it was released in July).
06 March 2025
Events
SEC Enforcement Landscape: Lessons and Trends for Advisers
The SEC Enforcement program continues to aggressively pursue advisers on all fronts. This panel will discuss lessons from recent enforcement actions and insight into agency priorities that adviser legal and compliance personnel can incorporate into their firms’ compliance programs. Foley Partner Jim Lundy will moderate.